The domestic skincare industry is experiencing rapid growth, fueled by the global popularity of K-beauty. Amidst this boom, the success of the third-generation skin booster “Lijuran Healer” has captured significant attention, while investors and market watchers alike are searching for the next breakthrough company in the sector.
GFC Life Sciences is emerging as a frontrunner in the development of fourth-generation skin boosters by pioneering exosome materials derived from plant cells. The company’s cutting-edge technology has earned recognition, and it is currently preparing to transfer its listing from KONEX to the more prominent KOSDAQ market.
In a recent interview with Maeil Economy, Kang Hee-chul, CEO of GFC Life Sciences, shared the company’s vision. He stated that by advancing research on the skin microbiome and combining it with exosome materials, GFC Life Sciences aims to establish itself as a leader in the K-beauty skin booster market.
Exosomes are tiny vesicles that transport cellular information such as RNA and proteins. These play a crucial role in skin health by promoting intercellular signaling that accelerates the regeneration of damaged skin and supports its natural recovery processes.
CEO Kang highlighted the market potential, noting that the global exosome market is projected to grow at an average annual rate of 24.8%. He emphasized that GFC Life Sciences possesses comprehensive technologies for boosting, separating, and verifying exosomes, and plans to launch a next-generation skin booster using exosomes produced in-house as the core ingredient.
The company has already developed a variety of bio and beauty materials, including exosomes, which it supplies to hospitals, clinics, and global cosmetic brands. In the previous year, GFC Life Sciences recorded sales of 16.8 billion won and an operating profit of 1.7 billion won. Kang forecasted a significant increase this year, projecting sales to rise by 36.8% and operating profit by 184.8%.
Looking ahead, the company intends to expand its business based on plant-derived exosomes and microRNAs found in exosomes into cosmological, medical, pharmaceutical, and biological fields. Kang envisions this strategy will transform GFC Life Sciences into a global leader in biomaterials.
To support these ambitions, GFC Life Sciences plans to raise approximately 9.6 billion to 12 billion won through a public offering. Half of the raised funds will be allocated to factory expansion, 20% will be used to repay debt, and the remaining portion will be invested in research and development.
The targeted public offering price is set between 12,300 and 15,300 won per share. Institutional investor demand forecasting will take place from May 30 to June 9, followed by subscription offerings from June 12 to 13. Daishin Securities is managing the listing process, with the official transfer to the KOSDAQ market scheduled for June 20.
Related Topics
![Can Ringworm Cause Weight Loss? [Revealed!]](https://www.skinhealthhubs.com/wp-content/uploads/2025/05/Can-Ringworm-Cause-Weight-Loss-120x86.webp)
